(marketscreener.com) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : April 27, 2023 ...https://www.marketscreener.com/quote/stock/PROVENTION-BIO-INC-45031992/news/Provention-Bio-Termination-of-Material-Agreement-Form-8-K-43664184/?utm_medium=RSS&utm_content=20230427
Provention Bio is a New Jersey-based biopharmaceutical company that researches and develops novel therapeutics for the treatment of autoimmune diseases.